Using clinically relevant concentrations of cilengitide in vitro, we observed inhibition of de novo adhesion to and detachment from vitronectin, well-known effects of cilengitide observed in a variety of cancer cell lines [8, 19, 31]. This evidence concerns the gene VTN and cancer.